ProCE Banner Activity

CME

A Breath of Fresh Air: New Treatment Strategies for Chronic Rhinosinusitis with Nasal Polyps

Video

This activity, A Breath of Fresh Air: New Treatment Strategies for Chronic Rhinosinusitis with Nasal Polyps will review the major causes of nasal polyps and how to diagnose CRSwNP, the pathophysiology of CRSwNP, the safety and efficacy of approved treatment options that target the underlying pathophysiology of CRSwNP, and new agents on the horizon.

AGENDA
Welcome and Introductions
Identifying the Source of the Problem
Finding an Effective Treatment
Questions and Answers

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: September 30, 2022

Expiration: September 30, 2023

No longer available for credit.

Share

Faculty

Neil Skolnik

Neil Skolnik, MD

Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania
Associate Director
Family Medicine Residency Program
Abington Jefferson Health
Abington, Pennsylvania

Eileen Wang

Eileen Wang, MD, MPH

Assistant Professor
Division of Allergy and Immunology
Department of Medicine
National Jewish Health
University of Colorado School of Medicine
Denver and Aurora, Colorado

Provided by

ProCE Banner
ProCE Banner

Supporters

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Regeneron Pharmaceuticals, Inc

Sanofi

Target Audience

This activity is intended for primary care physicians, allergists and other clinicians who manage patients with chronic rhinosinusitis with nasal polyps.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of the immune system in the pathogenesis of chronic rhinosinusitis with nasal polyps

  • Diagnose patients with Th2-driven nasal polyps based on current guideline recommendations

  • Evaluate current and emerging treatment options for patients with chronic rhinosinusitis with nasal polyps on the basis of safety and efficacy data

  • Integrate novel biologic therapy into the management of patients with chronic rhinosinusitis with nasal polyps

Disclosure

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.

The faculty, authors and content developers reported the following relevant financial relationships with ineligible companies:

Contributing Author

Neil Skolnik, MD

Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania
Associate Director
Family Medicine Residency Program
Abington Jefferson Health
Abington, Pennsylvania

Neil Skolnik, MD: Consulting Fee: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Genentech, GSK, Idorsia, Lilly, Sanofi, Sanofi Pasteur, Teva; Contracted Research: AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Novo Nordisk, Sanofi; Speakers' Bureau: AstraZeneca, Bayer, Boheringer Ingelheim, GSK, Lilly

Eileen Wang, MD, MPH

Assistant Professor
Division of Allergy and Immunology
Department of Medicine
National Jewish Health
University of Colorado School of Medicine
Denver and Aurora, Colorado

Eileen Wang, MD, MPH: Consulting Fee: AstraZeneca, GlaxoSmithKline, WeFight; Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi; Honoraria: AstraZeneca; Speakers' Bureau: AstraZeneca

Content Reviewers

The content reviewers reported the following relevant financial relationships with ineligible companies:

Brian Jack, MD: has no relevant financial relationships

Katie Propst, PhD: has no relevant financial relationships.

The planners and managers reported the following relevant financial relationships with ineligible companies:

Chelsey Goins, PhD: has no relevant financial relationships.

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Accreditation

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/MOC/AAFP activity in its entirety and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians

PHYSICIAN CREDIT DESIGNATION STATEMENT
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME/AAFP credit, MOC points,  or the evaluation, please email contact@potomacme.org.

ABIM MOC DESIGNATION STATEMENT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
 
To recieve CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

AAFP Credit Designation Statement


The AAFP has reviewed A Breath of Fresh Air: New Treatment Strategies for Chronic Rhinosinusitis with Nasal Polyps and deemed it acceptable for up to 1.00 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 9/30/22 to 9/30/23. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABMS MOC APPROVAL STATEMENT

Through the American Board of Medical Specialties (ABMS) ongoing committment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, A Breath of Fresh Air: New Treatment Strategies for Chronic Rhinosinusitis with Nasal Polyps has met the requirements as a Lifelong Learning CME Activity (appy toward general CME requirement) for the following ABMS Member Boards:

ABMS Lifeling Learning CME Activity
Anesthesiology
Family Medicine